Drug Profile
Pexelizumab
Alternative Names: 5G1.1-SC; Anti-C5 monoclonal antibody 5G1-1-SC; h5G1.1-scFV; Monoclonal antibody 5G1.1-SC; Short-acting monoclonal antibody 5G1.1Latest Information Update: 29 Jul 2021
Price :
$50
*
At a glance
- Originator Stanford University
- Class Anti-inflammatories; Monoclonal antibodies
- Mechanism of Action Complement C5 inhibitors; Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Myocardial infarction; Reperfusion injury
Most Recent Events
- 21 Jul 2021 Alexion Pharmaceuticals has been acquired by AstraZeneca and changed its name to Alexion AstraZeneca Rare Disease
- 07 May 2007 Proctor & Gamble terminates its licence for pexelizumab worldwide
- 28 Jun 2006 Interim results from a phase III clinical trial (APEX-AMI) in patients with myocardial infarction have been added to the Ischaemic Heart Disease therapeutic trials section